Peptides and GLP-1 Drugs After Cancer: What Survivors Should Know

Many cancer survivors are now asking about two kinds of peptide drugs. The first group is GLP-1 drugs such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), which are approved for diabetes and weight loss. The second group is unapproved "wellness" peptides such as BPC-157, TB-500, and growth hormone boosters, which are sold for healing, muscle, and anti-aging.

The two groups raise very different questions. For GLP-1 drugs, there is real human data, and recent studies have not found that they raise cancer risk overall; the main open questions are practical ones about weight, muscle, and other medicines. For the wellness peptides, the worry is about how they work: several are promoted because they boost growth signals or blood vessel growth, and those same signals can help tumors. Direct studies of these peptides in cancer survivors do not exist.

Nothing here replaces advice from your oncology team, which knows your cancer type, treatment, and risk of recurrence.

After cancer treatment, many people gain weight, develop diabetes, or lose muscle and strength. Extra weight is linked to a higher risk of several cancers, so losing it can seem like a natural goal.

At the same time, survivors have reasons to be more careful than the general public. A drug that is harmless for most people could matter more for someone whose cancer might return. Survivors also often take other long-term medicines, and new drugs can change how those work. That is why the same question, "Is this peptide safe?", can have a different answer for a survivor than for a healthy 30-year-old.

GLP-1 drugs mimic a gut hormone that lowers blood sugar and reduces appetite. Our guide to GLP-1s and cancer covers the large body of research on cancer prevention and risk in detail. Two studies from October 2026 add to it.

The first looked at who uses these drugs. In a national survey of 3,615 U.S. adults with diabetes, published in JAMA Network Open, 20.5% of those with a history of cancer used an injectable GLP-1 drug, compared with 26.5% of those without one, after adjusting for other differences. The gap was no longer statistically clear when the analysis was limited to type 2 diabetes. The authors said the survey cannot tell whether survivors are less likely to qualify, whether doctors are more cautious, or whether patients choose not to use the drugs.

The second looked at endometrial cancer, the cancer most strongly linked to obesity. In a health-records study of 176,981 matched pairs of women with overweight or obesity, women who started tirzepatide had about 28% fewer new endometrial cancer diagnoses over two years than women in lifestyle programs (hazard ratio 0.717). This was an observational study, and the authors said it does not show that tirzepatide prevents the cancer.

One warning applies to everyone. Wegovy, Ozempic, Zepbound, and Mounjaro carry a boxed warning because these drugs caused thyroid C-cell tumors in rodents. They should not be used by people with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN 2). It is unknown whether they cause these tumors in humans.

GLP-1 drugs slow the emptying of the stomach. Their labels say this can affect how well other medicines taken by mouth are absorbed, and the Wegovy label advises closer monitoring for oral medicines that need steady blood levels. Many survivors take pills for years after treatment, including hormone therapies and targeted cancer drugs, so ask your oncologist or pharmacist whether any of your medicines need extra checks.

Muscle is another concern. Weight loss on these drugs includes some lean mass, meaning muscle and other tissue that is not fat. Survivors who lost muscle during chemotherapy or radiation may have less to spare. Eating enough protein and doing resistance exercise can help protect muscle during weight loss; our guides to muscle loss on GLP-1 drugs and weight-loss peptides and muscle cover what is known.

Finally, GLP-1 drugs are meant for people who need to lose weight or control diabetes. A survivor who is underweight, still recovering, or losing weight without trying needs a different conversation.

Several popular wellness peptides are sold to raise growth hormone. CJC-1295 and ipamorelin act on the pituitary gland, and MK-677 (ibutamoren) is a pill that mimics the hunger hormone ghrelin. They work by increasing growth hormone, which in turn raises IGF-1, a growth signal made mainly in the liver. In a 2006 trial in healthy adults, a single CJC-1295 injection raised IGF-1 levels 1.5- to 3-fold for more than a week. In a two-year trial in older adults, daily MK-677 raised growth hormone and IGF-1 to the levels of young adults.

IGF-1 is the reason oncologists pay attention. In the UK Biobank, a study of about 394,000 people, higher blood IGF-1 levels were linked to higher risks of colorectal, breast, prostate, and thyroid cancer. That kind of study shows a link, not proof that raising IGF-1 with a drug causes cancer.

The approved form of growth hormone shows how regulators handle the risk. The label for somatropin says it should generally not be used in people with active cancer, that any earlier cancer should be inactive and treated first, and that it should be stopped if cancer returns. It also reports a higher risk of a second tumor, mostly meningiomas, in childhood cancer survivors who had radiation to the head and were then treated with growth hormone. The wellness peptides have never been tested this carefully.

BPC-157 is promoted for healing injuries and the gut. In a 2017 study in rats and human blood vessel cells, it increased blood vessel growth, partly by raising levels of VEGFR2, a receptor that responds to the growth signal VEGF. New blood vessels help wounds heal, but tumors also need them to grow, which is why some cancer drugs block this pathway. No study has tested whether BPC-157 affects cancer in people. Our article on BPC-157 gut-healing evidence covers the wider research.

TB-500 is a fragment of thymosin beta-4, a natural protein involved in cell movement and repair. In a 2004 study, colon cancer cells that made extra thymosin beta-4 became more invasive, and tumors that had spread to the liver had higher levels of it. Whether the short TB-500 fragment acts the same way is not known.

The FDA's list of bulk drug substances that may raise safety concerns in compounding says it has no, or only limited, safety information on BPC-157 for the proposed routes and no human exposure data on the TB-500 fragment, and it raises concerns about immune reactions and impurities. In 2026, federal officials began moving to loosen compounding limits on some of these peptides; our explainer on the FDA panel vote covers what that does and does not change. Looser rules would not create new safety data for survivors.

These questions can help you and your care team weigh the options:

• Would losing weight lower my risk, given my type of cancer and treatment?
• Do I have a personal or family history of medullary thyroid cancer or MEN 2?
• Could a GLP-1 drug change how my oral cancer medicines or hormone pills are absorbed?
• How can I protect my muscle and strength if I start a weight-loss drug?
• Is my cancer type sensitive to growth signals such as IGF-1?
• What is in the peptide I am considering, who makes it, and has it been tested in people like me?

If you already use a wellness peptide, tell your oncology team. They cannot help you weigh the risks of something they do not know about.